We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 72.4%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
101
DELISTED
Vaxart
VXRT
$1.72M 0.02%
75,495
-2,976
-4% -$73.1K
BDSI
102
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.67M 0.01%
210,021
-45,845
-18% -$394K
MDWD icon
103
MediWound
MDWD
$186M
$1.59M 0.01%
32,143
– –
ALNY icon
104
Alnylam Pharmaceuticals
ALNY
$38.1B
$1.36M 0.01%
11,340
– –
TENX icon
105
Tenax Therapeutics
TENX
$399M
$1.31M 0.01%
+11
New +$1.25M
ALDX icon
106
Aldeyra Therapeutics
ALDX
$95.3M
$1.1M 0.01%
142,000
– –
NBSE
107
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$930K 0.01%
926
– –
XLRN
108
DELISTED
Acceleron Pharma
XLRN
$910K 0.01%
28,765
– –
QURE icon
109
uniQure
QURE
$2.76B
$810K 0.01%
30,000
– –
FMI
110
DELISTED
Foundation Medicine, Inc.
FMI
$707K 0.01%
20,892
-103,363
-83% -$4.16M
AKAO
111
DELISTED
Achaogen Inc
AKAO
$603K 0.01%
100,000
– –
FPRX
112
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$478K ﹤0.01%
19,247
– –
CCXI
113
DELISTED
ChemoCentryx, Inc.
CCXI
$404K ﹤0.01%
49,064
– –
APTO
114
DELISTED
Aptose Biosciences, Inc.
APTO
$170K ﹤0.01%
74
– –
BTX.WS
115
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$23K ﹤0.01%
20,084
– –
LPCN icon
116
Lipocine
LPCN
$17.3M
– –
-28,775
Closed -$3.38M
MDGL icon
117
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-13,973
Closed -$949K
OSUR icon
118
OraSure Technologies
OSUR
$274M
– –
-229,397
Closed -$1.5M
RIGL icon
119
Rigel Pharmaceuticals
RIGL
$712M
– –
-35,719
Closed -$1.27M
EIGR
120
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-815
Closed -$6.95M
INFI
121
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-305,037
Closed -$4.26M
ALBO
122
DELISTED
Albireo Pharma Inc
ALBO
– –
-1,006
Closed -$36K
AEGR
123
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-14,300
Closed -$374K
GEVA
124
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-11,660,432
Closed -$1.14B
PCYC
125
DELISTED
PHARMACYCLICS INC
PCYC
– –
-9,039,652
Closed -$2.31B
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Baker Bros. Advisors held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 40% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Baker Bros. Advisors's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Baker Bros. Advisors's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Baker Bros. Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Baker Bros. Advisors opened 10 new positions and closed 12 in Q2 2015.
  • Baker Bros. Advisors's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.